Compass Therapeutics’ (CMPX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research note published on Wednesday morning,Benzinga reports. They currently have a $30.00 target price on the stock.

Several other research firms have also recently weighed in on CMPX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Wednesday, October 8th. Guggenheim increased their target price on Compass Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, August 12th. Lifesci Capital initiated coverage on Compass Therapeutics in a research report on Monday, October 6th. They issued an “outperform” rating and a $10.00 price target for the company. Finally, Compass Point set a $10.00 price target on shares of Compass Therapeutics in a research note on Monday, October 6th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $12.90.

Compass Therapeutics Trading Up 5.8%

Compass Therapeutics stock opened at $4.23 on Wednesday. The firm has a market cap of $584.94 million, a P/E ratio of -9.40 and a beta of 1.48. Compass Therapeutics has a 1-year low of $1.27 and a 1-year high of $4.86. The firm has a 50-day moving average of $3.78 and a 200-day moving average of $2.97.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.06. Research analysts forecast that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Institutional Trading of Compass Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Vontobel Holding Ltd. bought a new position in Compass Therapeutics during the first quarter valued at approximately $57,000. American Century Companies Inc. purchased a new stake in Compass Therapeutics during the 1st quarter valued at $140,000. Wellington Management Group LLP purchased a new stake in Compass Therapeutics during the 1st quarter valued at $423,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Compass Therapeutics by 4.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 297,880 shares of the company’s stock valued at $566,000 after buying an additional 11,689 shares during the period. Finally, Nuveen LLC purchased a new position in shares of Compass Therapeutics in the 1st quarter worth $579,000. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.